The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes

J. Campbell, Syed M. Mohiuddin

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. Dyslipidemia is an important modifiable risk factor. Mixed dyslipidemia (low high-density lipoprotein cholesterol [HDL-C], elevated triglycerides and a high percentage of small, dense low-density lipoprotein cholesterol [LDL-C]) is a common lipid disorder in diabetics and is considered especially atherogenic. Research suggests that in patients with dyslipidemia, combination therapy with fibrates and statins may be more effective than statin monotherapy alone. The choline salt of fenofibric acid (choline fibrate) is indicated for the treatment of mixed dyslipidemia, either as a single treatment or in combination with statin therapy. It does not require first-pass metabolism, but dissociates in the gastrointestinal tract into the pharmacologically active fenofibric acid. This new formulation of fenofibric acid in combination with a low or moderate dose of statin has been shown to be effective in Increasing HDL-C and lowering triglycerides beyond that provided by statin monotherapy alone. The ACCORD trial failed to show a mortality or morbidity benefit after combination therapy, although the data suggested that combination therapy may benefit patients with mixed dyslipidemia.

Original languageEnglish
Pages (from-to)757-764
Number of pages8
JournalDrugs of Today
Volume46
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dyslipidemias
Type 2 Diabetes Mellitus
LDL Cholesterol
HDL Cholesterol
Triglycerides
Therapeutics
Fibric Acids
Choline
Gastrointestinal Tract
fenofibric acid
Cardiovascular Diseases
Salts
Morbidity
Lipids
Mortality
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. / Campbell, J.; Mohiuddin, Syed M.

In: Drugs of Today, Vol. 46, No. 10, 10.2010, p. 757-764.

Research output: Contribution to journalReview article

@article{b2aaea9a30584bdf957a78b39bb9a9a3,
title = "The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes",
abstract = "Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. Dyslipidemia is an important modifiable risk factor. Mixed dyslipidemia (low high-density lipoprotein cholesterol [HDL-C], elevated triglycerides and a high percentage of small, dense low-density lipoprotein cholesterol [LDL-C]) is a common lipid disorder in diabetics and is considered especially atherogenic. Research suggests that in patients with dyslipidemia, combination therapy with fibrates and statins may be more effective than statin monotherapy alone. The choline salt of fenofibric acid (choline fibrate) is indicated for the treatment of mixed dyslipidemia, either as a single treatment or in combination with statin therapy. It does not require first-pass metabolism, but dissociates in the gastrointestinal tract into the pharmacologically active fenofibric acid. This new formulation of fenofibric acid in combination with a low or moderate dose of statin has been shown to be effective in Increasing HDL-C and lowering triglycerides beyond that provided by statin monotherapy alone. The ACCORD trial failed to show a mortality or morbidity benefit after combination therapy, although the data suggested that combination therapy may benefit patients with mixed dyslipidemia.",
author = "J. Campbell and Mohiuddin, {Syed M.}",
year = "2010",
month = "10",
doi = "10.1358/dot.2010.46.10.1519652",
language = "English",
volume = "46",
pages = "757--764",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes

AU - Campbell, J.

AU - Mohiuddin, Syed M.

PY - 2010/10

Y1 - 2010/10

N2 - Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. Dyslipidemia is an important modifiable risk factor. Mixed dyslipidemia (low high-density lipoprotein cholesterol [HDL-C], elevated triglycerides and a high percentage of small, dense low-density lipoprotein cholesterol [LDL-C]) is a common lipid disorder in diabetics and is considered especially atherogenic. Research suggests that in patients with dyslipidemia, combination therapy with fibrates and statins may be more effective than statin monotherapy alone. The choline salt of fenofibric acid (choline fibrate) is indicated for the treatment of mixed dyslipidemia, either as a single treatment or in combination with statin therapy. It does not require first-pass metabolism, but dissociates in the gastrointestinal tract into the pharmacologically active fenofibric acid. This new formulation of fenofibric acid in combination with a low or moderate dose of statin has been shown to be effective in Increasing HDL-C and lowering triglycerides beyond that provided by statin monotherapy alone. The ACCORD trial failed to show a mortality or morbidity benefit after combination therapy, although the data suggested that combination therapy may benefit patients with mixed dyslipidemia.

AB - Diabetes, due to its multifactorial effects, increases the risk of developing cardiovascular disease. Dyslipidemia is an important modifiable risk factor. Mixed dyslipidemia (low high-density lipoprotein cholesterol [HDL-C], elevated triglycerides and a high percentage of small, dense low-density lipoprotein cholesterol [LDL-C]) is a common lipid disorder in diabetics and is considered especially atherogenic. Research suggests that in patients with dyslipidemia, combination therapy with fibrates and statins may be more effective than statin monotherapy alone. The choline salt of fenofibric acid (choline fibrate) is indicated for the treatment of mixed dyslipidemia, either as a single treatment or in combination with statin therapy. It does not require first-pass metabolism, but dissociates in the gastrointestinal tract into the pharmacologically active fenofibric acid. This new formulation of fenofibric acid in combination with a low or moderate dose of statin has been shown to be effective in Increasing HDL-C and lowering triglycerides beyond that provided by statin monotherapy alone. The ACCORD trial failed to show a mortality or morbidity benefit after combination therapy, although the data suggested that combination therapy may benefit patients with mixed dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=79952199914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952199914&partnerID=8YFLogxK

U2 - 10.1358/dot.2010.46.10.1519652

DO - 10.1358/dot.2010.46.10.1519652

M3 - Review article

VL - 46

SP - 757

EP - 764

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 10

ER -